Have a personal or library account? Click to login
Preliminary in vitro investigation of docetaxel nanomedicines based on cetyl palmitate for inhibition of prostate cancer cells' growth Cover

Preliminary in vitro investigation of docetaxel nanomedicines based on cetyl palmitate for inhibition of prostate cancer cells' growth

European Pharmaceutical Journal
AHEAD OF PRINT
By: Chukwuma O. Agubata,  Rajan Bhattarai,  Akachukwu Ibezim,  Onyinyechi L. Ugorji,  Calister E. Ugwu and  Godswill C. Onunkwo  
Open Access
|Nov 2025

Authors

Chukwuma O. Agubata

chukwuma.agubata@unn.edu.ng

Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, USA

Rajan Bhattarai

Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, USA

Akachukwu Ibezim

Department of Pharmaceutical and Medicinal Chemistry, University of Nigeria Nsukka, Nigeria

Onyinyechi L. Ugorji

Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria

Calister E. Ugwu

Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria

Godswill C. Onunkwo

Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria
DOI: https://doi.org/10.2478/afpuc-2025-0008 | Journal eISSN: 2453-6725
Journal RSS Feed
Language: English
Submitted on: Feb 2, 2025
Accepted on: Aug 26, 2025
Published on: Nov 7, 2025
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Docetaxel,
nanoparticles,
prostate cancer
Related subjects:
Pharmacy,
Pharmacy, other

© 2025 Chukwuma O. Agubata, Rajan Bhattarai, Akachukwu Ibezim, Onyinyechi L. Ugorji, Calister E. Ugwu, Godswill C. Onunkwo, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT